Fibrosis is a detrimental outcome of most chronic inflammatory disorders and is defined by
the buildup of excess extracellular matrix (ECM) components, which eventually leads to …

Fibrosis is the abnormal deposition of extracellular matrix, characterized by accumulation of
collagen and other extracellular matrix components, which causes organ dysfunction and …

Peritoneal dialysis (PD) is an efficient renal replacement therapy for patients with end-stage
renal disease. Even if it ensures an outcome equivalent to hemodialysis and a better quality …

Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis,
angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically …

Fibrosis is defined as the pathological progress of excessive extracellular matrix (ECM),
such as collagen, fibronectin, and elastin deposition, as the regenerative capacity of cells …

Peritoneal dialysis (PD) is an important, if underprescribed, modality for the treatment of
patients with end-stage kidney disease. Among the barriers to its wider use are the …

Peritoneal fibrosis (PF) is a pathophysiological condition caused by a variety of pathogenic
factors. The most important features of PF are mesothelial–mesenchymal transition and …

Peritoneal dialysis (PD) is a feasible and effective renal replacement therapy (RRT) thanks
to the dialytic properties of the peritoneal membrane (PM). Preservation of PM integrity and …

Peritoneal dialysis (PD) is a widely accepted renal replacement therapy for patients with end-
stage renal disease (ESRD). Morphological and functional changes occur in the peritoneal …

Peritoneal fibrosis contributes to ultrafiltration failure in peritoneal dialysis (PD) patients and
thus restricts the wide application of PD in clinic. Recently we have demonstrated that …